ProjectEPILOC – Post-COVID-19 Erkrankungen – Charakterisierung eines neuen Krankheitsbildes und Entwicklung einer…

Basic data

Post-COVID-19 Erkrankungen – Charakterisierung eines neuen Krankheitsbildes und Entwicklung einer Grundlage für therapeuti-sche Interventionen
8/1/2021 to 7/31/2022
Abstract / short description:
Persistent symptoms after COVID-19 ("Long-Covid ") in the sense of a fatigue syndrome with partly residual lesions in the cardiovascular and pulmonary areas and/or neurocognitive impairments (concentration, attention, memory) seem to be frequent in convalescence after severe acute COVID-19 disease, but are also observed after initially mild disease. The exact frequency of actual longer-term (>6 months) impairments with relevance to quality of life and work capacity is unknown. Variations in frequency are extreme, ranging from <10% to >50%. However, in almost all previous studies on the frequency of the syndrome, the complaints are also not medically validated. Prognoses on spontaneous regression or even efficacy of (non-specific) rehabilitation measures or even, for example, a therapeutic vaccination in this case are currently not possible.
EPILOC proceeds in two phases: In phase 1 (July-September), about 50,000 SARS-CoV-2 infected persons (18-65 years old) from the period October 2020 to March 2021 (acute infection i.e. >6 months ago) will be invited to participate in a questionnaire survey (from the regions around the university hospitals FR, HD, TÜ and UL) and will be asked about current complaints and limitations - phase 1 should and can quickly provide population-based data.
In phase 2a (October to February) - after evaluation of the questionnaires - "cases" of Long-Covid suspicion are defined (persistent complaint complexes WITH restrictions of quality of life and/or ability to work), of which about 1,000 are promptly comprehensively followed up in the university hospitals - incl. performance tests (e.g. lung function tests not only at rest, but also under stress), psychological tests, laboratory tests. In addition, control subjects without evidence of Long-Covid will be invited from the questionnaire population to evaluate the actual limitations of the "cases" in comparison to post-covid patients without alleged Long-Covid symptoms and to detect possible biomedical abnormalities as potential risk factors.
In Phase 2b (May to July), selected Long-Covid patients ("cases") will be invited again for an overnight examination (question: prognosis of symptoms depending on biomedical, social and also therapeutic factors). Phase 2 aims to and can thus for the first time provide clinically validated data on Long-Covid and thus evaluate and also, if necessary, correct the epidemiology and prognosis estimates. In phase 2, biomaterials will continue to be preserved, if patients/subjects agree, in order to be able to test further hypotheses on biological risk factors.
Persistent symptoms

Involved staff


Faculty of Medicine
University of Tübingen
Faculty of Medicine
University of Tübingen

Local organizational units

Internal Medicine Department I
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine

will be deleted permanently. This cannot be undone.